OR WAIT null SECS
April 19, 2024
Video
Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.
A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.
April 16, 2024
Article
The FDA approved ustekinumab-aekn for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
Fresenius announced the immediate availability of its tocilizumab biosimilar, tocilizumab-aazg (Tyenne), in the US.
April 13, 2024
A new study showed secukinumab was not superior to Sandoz adalimumab (SDZ-ADL; TNF inhibitor) in terms of similar low rates of radiographic progression and safety profiles.
The proposed insulin glargine biosimilar (Basalin) showed comparable immunogenicity, efficacy, and safety to the originator (Lantus) in a phase 3 equivalence trial.
April 12, 2024
A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.
Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.
April 11, 2024
A new study provides insight into the effectiveness of IFX-dyyb in a real-world US population of RA patients, showing how the biosimilar compares to other treatments.
April 09, 2024
A number of biosimilar options to treat the common retina diseases are in development globally. Here’s a highlight of 9 with supporting late-stage data.